VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

EAN 2021 | How to individualize MS treatment decisions?

Mar Tintoré, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, discusses how to individualize treatment decisions in daily routine practice. Firstly, Dr Tintoré gives an overview of the factors contributing to the prognosis of multiple sclerosis (MS) and highlights how the disease’s natural history is changing in the treated era. Dr Tintoré discusses the tools available for identifying patients who are at a high risk of developing aggressive disease. These tools include looking at the clinical picture, such as age at disease onset, how well patients recover after an attack, using imaging techniques like magnetic resonance imaging (MRI) to determine the number and topography of lesions in the central nervous system, and using biomarkers such as serum neurofilament. Finally, Dr Tintoré emphasizes the importance of early, high-efficacy treatment. This interview took place during the European Academy of Neurology 2021 congress.


Consulting services and speaking honoraria from: Almirall, Bayer Schering Pharma, Biogen-Idec, Genzyme, Jansen, Merck-Serono, Novartis, Roche, Sanofi-Aventis, Viela Bio and Teva Pharmaceuticals.
Receipt grants and research supports from: Carlos III Health Institute, Foundation Genzyme, Foundation Salud 2000. Biogen-Idec, Novartis.
Dr Tintoré is co-editor of Multiple Sclerosis Journal-ETC.